What are the recommended initial treatments for a Canadian adult patient with hypertension, considering lifestyle modifications and pharmacological interventions?

Canadian Hypertension Guidelines: Initial Treatment Recommendations

Lifestyle Modifications (Essential First-Line for All Patients)

All Canadian adults with hypertension should implement comprehensive lifestyle modifications as the foundation of treatment, with specific targets that differ from international guidelines. 1

Dietary Sodium Restriction

• Restrict sodium to 1500 mg (65 mmol) per day for adults ≤50 years, 1300 mg (57 mmol) per day for ages 51-70, and 1200 mg (52 mmol) per day for those >70 years 1
• This represents more aggressive sodium restriction than the 2300 mg/day recommended in earlier Canadian guidelines 2, 3

Physical Activity

• Perform 30-60 minutes of moderate aerobic exercise (walking, jogging, cycling, swimming) on 4-7 days per week 1, 2
• Add resistance/strength training on 2-3 days per week 4

Weight Management

• Maintain BMI between 18.5-24.9 kg/m² 1, 2
• Keep waist circumference <102 cm for men and <88 cm for women 1, 2
• Alternatively, maintain waist-to-height ratio <0.5 for all populations 4

Alcohol Limitation

• Limit to ≤14 standard drinks per week for men or ≤9 standard drinks per week for women 1, 2
• Avoid binge drinking 4

Dietary Pattern

• Follow a DASH-style diet emphasizing fruits, vegetables, low-fat dairy products, dietary and soluble fiber, whole grains, and plant-based protein 1, 2
• Reduce saturated fat and cholesterol intake 1, 2

Additional Considerations

• Smoking cessation is mandatory for all patients 4
• Consider stress management techniques including mindfulness or meditation in selected individuals 4, 1

---

Pharmacological Treatment Thresholds

Blood Pressure Targets

• Target <140/90 mmHg for all hypertensive patients 1, 2, 3
• Target <130/80 mmHg for patients with diabetes mellitus or chronic kidney disease 1, 2, 3

When to Initiate Drug Therapy

For BP 140-159/90-99 mmHg (Grade 1):

• Start immediate drug treatment in high-risk patients with cardiovascular disease (CVD), chronic kidney disease (CKD), diabetes mellitus (DM), or hypertension-mediated organ damage (HMOD) 4
• For low-to-moderate risk patients without these conditions, implement lifestyle interventions for 3-6 months first 4
• If BP remains uncontrolled after 3-6 months of lifestyle intervention, initiate pharmacological therapy in patients aged 50-80 years 4

For BP ≥160/100 mmHg (Grade 2):

• Start immediate drug treatment in all patients 4, 5
• Even in lower-risk patients, supply lifestyle intervention concurrently but do not delay pharmacotherapy 4

---

Initial Pharmacological Therapy Selection

For Adults Without Compelling Indications

The Canadian approach differs from international guidelines by emphasizing thiazide diuretics as preferred initial therapy for uncomplicated hypertension. 1, 2, 3

First-line options include:

• Thiazide diuretics (preferred for initial therapy) 1, 2, 3
• ACE inhibitors (in non-Black patients) 1, 2, 3
• Long-acting calcium channel blockers 1, 2, 3
• Angiotensin receptor blockers (ARBs) 1, 2, 3
• Beta-blockers (only in patients <60 years of age) 1, 2, 3

Race-Specific Considerations

For Black Patients:

• Start with ARB plus dihydropyridine calcium channel blocker (DHP-CCB) 5
• Alternative: DHP-CCB plus thiazide-like diuretic 5
• Do not use ACE inhibitors as monotherapy in Black patients 1, 2, 3

For Non-Black Patients:

• Start with low-dose ACE inhibitor or ARB (e.g., lisinopril 10 mg daily) 5, 6
• Alternative: thiazide diuretic as preferred first-line 1, 2, 3

Combination Therapy as Initial Treatment

Consider starting with two first-line agents if:

• Systolic BP is ≥20 mmHg above target 1, 2, 3
• Diastolic BP is ≥10 mmHg above target 1, 2, 3

Initial goal: Reduce BP by at least 20/10 mmHg 5

---

Disease-Specific First-Line Therapy

Coronary Artery Disease

• ACE inhibitors, ARBs, or beta-blockers are recommended 1

Cerebrovascular Disease

• ACE inhibitor/diuretic combination is preferred 1, 2, 3

Proteinuric Non-Diabetic Chronic Kidney Disease

• ACE inhibitors are recommended 1, 2, 3
• ARBs if intolerant to ACE inhibitors 1, 2

Diabetes Mellitus

• ACE inhibitors or ARBs as first-line 1, 2, 3
• In patients without albuminuria: thiazides or dihydropyridine CCBs are acceptable alternatives 1, 2, 3

Heart Failure or Recent Myocardial Infarction

• Beta-blockers and ACE inhibitors are recommended 2, 3

Isolated Systolic Hypertension

• Long-acting dihydropyridine CCBs or ARBs 1, 2, 3
• Thiazide diuretics are also appropriate 1

---

Combination Therapy Progression

Adding a Second Agent

When BP remains uncontrolled on monotherapy:

For patients on ACE inhibitor/ARB:

• Add calcium channel blocker (preferred) 5
• Alternative: add thiazide-like diuretic 5
• CCB is preferred over thiazide to reduce diabetes risk 5

For patients on calcium channel blocker:

• Add ACE inhibitor or ARB (provides complementary mechanisms and may reduce CCB-related peripheral edema) 7
• Alternative: add thiazide-like diuretic, particularly for Black patients, elderly patients, or those with volume-dependent hypertension 7

Triple Therapy

Standard triple therapy combination:

• ACE inhibitor/ARB + calcium channel blocker + thiazide/thiazide-like diuretic 5, 7

Optimize doses of existing agents before adding a third drug class 5

Fourth-Line Agent for Resistant Hypertension

If BP remains uncontrolled on optimized triple therapy:

• Add spironolactone 25-50 mg daily as the preferred fourth-line agent 5
• Monitor potassium closely when combining with ACE inhibitor or ARB 5

---

Critical Dosing Information

Lisinopril (Representative ACE Inhibitor)

• Initial dose: 10 mg once daily for hypertension 6
• Usual dosage range: 20-40 mg once daily 6
• Maximum studied dose: 80 mg daily (though doses >40 mg show minimal additional benefit) 6
• When adding diuretic: reduce lisinopril to 5 mg once daily initially 6
• Adjust for renal impairment: reduce initial dose to 5 mg if CrCl 10-30 mL/min 6

---

Important Contraindications and Cautions

Combination to Avoid

• Do not combine ACE inhibitors with ARBs unless compelling indications exist 1, 2
• This combination increases adverse events (hyperkalemia, acute kidney injury) without additional cardiovascular benefit 5, 7

Age Considerations

• Antihypertensive therapy should be considered in all adult patients regardless of age 1, 2, 3
• Exercise caution in elderly patients who are frail 1, 2, 3

---

Monitoring and Follow-Up

Initial Follow-Up

• Schedule follow-up within 2-4 weeks to assess response to therapy 5
• Monitor for medication adherence and side effects 5
• Aim to achieve target BP within 3 months 5

Home Blood Pressure Monitoring

• Consider home BP monitoring to track progress and improve adherence 5
• Home BP ≥135/85 mmHg confirms uncontrolled hypertension requiring treatment intensification 5

Specialist Referral

• Refer to hypertension specialist if BP remains uncontrolled despite multiple medications 5
• Consider referral for resistant hypertension (uncontrolled on ≥3 medications including a diuretic) 5
• Assess for secondary causes of hypertension in severe or resistant cases 5

---

Adjunctive Cardiovascular Risk Reduction

Lipid Management

• All hypertensive patients with dyslipidemia should be treated according to Canadian lipid treatment guidelines 1, 2, 3
• Selected high-risk hypertensive patients should receive statin therapy even if they don't meet traditional lipid thresholds 1, 2, 3

Antiplatelet Therapy

• Once BP is controlled, consider low-dose acetylsalicylic acid (aspirin) therapy 1, 2, 3

---

Common Pitfalls to Avoid

• Do not delay pharmacotherapy in Grade 2 hypertension (≥160/100 mmHg) while attempting lifestyle modifications alone 4, 5
• Do not use beta-blockers as first-line therapy in patients ≥60 years of age 1, 2, 3
• Do not use ACE inhibitors as monotherapy in Black patients 1, 2, 3
• Do not add a third drug class before optimizing doses of the current two-drug regimen 5
• Do not assume treatment failure without confirming medication adherence first 5
• Most patients require more than one agent to achieve target BP—do not hesitate to escalate therapy 1, 2, 3